Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.

Abstract

Transarterial chemoembolization (TACE) has been the standard treatment modality in patients with intermediate stage hepatocellular carcinoma (HCC). Brivanib is an oral small molecular inhibitor of both vascular endothelial growth factor and fibroblast growth factor receptors. Herein, we reported that a 67-year-old patient with intermediate stage HCC achieved the complete remission after TACE combined with brivanib therapy. This finding potentially suggested the benefit of this combination therapy for HCC.

• Authors: Jia Jia, Xingshun Qi, Wei Bai, Jie Yuan, Guohong Han
• Journal: Journal of cancer research and therapeutics (J Cancer Res Ther) 2014 Oct-Dec Vol. 10 Issue 4 Pg. 1112-4 ISSN: 1998-4138 [Electronic] India
• PMID: 25579566 (Publication Type: Case Reports, Letter)

Chemical References

• Antineoplastic Agents
• Receptors, Fibroblast Growth Factor
• Triazines
• Vascular Endothelial Growth Factor A
• brivanib
• Alanine

Topics

• Aged
• Alanine (analogs & derivatives, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy)
• Chemoembolization, Therapeutic
• Disease Progression
• Humans
• Liver Neoplasms (drug therapy)
• Male
• Receptors, Fibroblast Growth Factor (metabolism)
• Remission Induction
• Treatment Outcome
• Triazines (therapeutic use)
• Vascular Endothelial Growth Factor A (metabolism)